Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Equivalents: 2015-2024

Historic Cash & Equivalents for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $154.1 million.

  • Syndax Pharmaceuticals' Cash & Equivalents fell 12.19% to $116.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.8 million, marking a year-over-year decrease of 12.19%. This contributed to the annual value of $154.1 million for FY2024, which is 47.84% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Cash & Equivalents of $154.1 million as of FY2024, which was down 47.84% from $295.4 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Cash & Equivalents ranged from a high of $295.4 million in FY2023 and a low of $74.4 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $174.6 million, with a median of $154.1 million in 2024.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Cash & Equivalents surged by 366.58% in 2020, and later slumped by 66.52% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash & Equivalents (Yearly) stood at $115.4 million in 2020, then spiked by 92.51% to $222.1 million in 2021, then plummeted by 66.52% to $74.4 million in 2022, then spiked by 297.27% to $295.4 million in 2023, then crashed by 47.84% to $154.1 million in 2024.